Progress with interferon in CML - Results of the MRC UK CML III Study

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Shepherd, P C A ^a   Richards, S M ^b   Allan, N C ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Busulphan randomised trial; Chronic myeloid leukaemia; Hydroxyurea; Interferon

Indexed keywords

ALPHAN1 INTERFERON; BUSULFAN; CYTOKINE; HYDROXYUREA;

ADULT; AGED; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BUSULFAN; GREAT BRITAIN; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTE COUNT; MIDDLE AGED; SURVIVAL RATE;

EID: 0029929777     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991; 114: 532-538.
2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
3. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood 1994; 84: 4064-4077.
4. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomised trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
5. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.
6. Kluin-Nelemans JC, Louwagie A, Delannoy A et al. CML treated by interferon alfa-2b versus hydroxyurea alone: preliminary report of a large multicenter randomized trial. Blood 1992; 80 (Suppl. 1): 358a.
7. Schofield JR, Robinson WA, Murphy JR et al. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 121: 736-744.